Nitin H. Shirole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nitin H. Shirole has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- William G. Kaelin
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
26 shared publications - Amy Goodale
Broad Institute, Cambridge, MA, USA
25 shared publications - Devishi Kesar
Broad Institute, Cambridge, United States
25 shared publications - Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
25 shared publications - John G. Doench
Genetic Perturbation Platform, Broad Institute, Cambridge, USA
25 shared publications - Karen Adelman
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, USA
25 shared publications
Latest Publications
- Open Access
HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors
Kidney cancer frequently causes paraneoplastic syndromes, including hypercalcemia and cachexia, but the underlying mechanisms are incompletely understood. The most common form of kidney cancer, clear cell renal cell carcinoma, is frequently caused by loss of the pVHL tumor suppressor protein and the resulting upregulation of the HIF2 transcription factor. We show that PTHLH , which resides on a ccRCC amplicon on chromosome 12p, is a direct HIF2 transcriptional target in ccRCC. Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in ccRCC patients, including in some patients who did not exhibit objective tumor shrinkage.
Open AccessHIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors
Kidney cancer frequently causes paraneoplastic syndromes, including hypercalcemia and cachexia, but the underlying mechanisms are incompletely understood. The most common form of kidney cancer, clear cell renal cell carcinoma, is frequently caused by loss of the pVHL tumor suppressor protein and the resulting upregulation of the HIF2 transcription factor. We show that PTHLH , which resides on a ccRCC amplicon on chromosome 12p, is a direct HIF2 transcriptional target in ccRCC. Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in ccRCC patients, including in some patients who did not exhibit objective tumor shrinkage.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S8. Sequences of Oligonucleotides Used to Determine the Efficiency of Cas9 Gene Editing at the RB1, RBL1, and RBL2 Loci
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S8. Sequences of Oligonucleotides Used to Determine the Efficiency of Cas9 Gene Editing at the RB1, RBL1, and RBL2 Loci
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S13 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S13: Sustained Expression of CCND1 Alone is Not Sufficient to Confer Resistance to PT2399 In Vivo
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S13 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S13: Sustained Expression of CCND1 Alone is Not Sufficient to Confer Resistance to PT2399 In Vivo